European Hematology Association Congress 2022
Building connections, pioneering therapies.
Agios Events and Presentations
EHA 2022 Data Room
View our latest news and presentations from the EHA Annual Meeting
News
June 10, 2022
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
May 12, 2022
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
Events
June 13, 2022 | 8:00 AM ET
Join our investor event to learn more about our key clinical oral and poster presentations from this year’s EHA meeting.
Abstracts
Access All EHA Abstracts
Agios Presentations
Poster Presentations:
Title: Long-term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults With Non–transfusion-dependent Alpha- or Beta-thalassemia
Session date and time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1522
Presenting Author: Kevin H. M. Kuo, M.D., Division of Hematology, University of Toronto, Toronto, Canada
Learn More >
Title: Comorbidities and Complications Across Genotypes in Adult Patients With Pyruvate Kinase Deficiency: Analysis From the Peak Registry
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1542
Presenting Author: Andreas Glenthøj, M.D., Department of Hematology, Rigshospitalet Copenhagen, Denmark
Learn More >
Title: Mitapivat Decreases the Need for Transfusions Secondary to Poorly Tolerated Anemia and Acute Events Compared to Placebo in Patients With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1543
Presenting Author: Hanny Al-Samkari, M.D., Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Learn More >
Title: Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-term Treatment With Mitapivat
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1544
Presenting Author: Hanny Al-Samkari, M.D., Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Learn More >
Title: Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained Over Time in Patients With Pyruvate Kinase Deficiency Treated With Mitapivat in a Long-term Extension Study
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1545
Presenting Author: Rachael F. Grace, M.D., Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, United States
Learn More >
Title: ACTIVATE-kidsT: Mitapivat in Children With Pyruvate Kinase Deficiency Who Are Regularly Transfused
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1546
Presenting Author: Rachael F. Grace, M.D., Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, United States
Learn More >
Title: ACTIVATE-kids: Mitapivat in Children With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1547
Presenting Author: Rachael F. Grace, M.D., Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, United States
Learn More >
Title: Long-term Treatment With Oral Mitapivat Is Associated With Normalization of Hemoglobin Levels in Patients With Pyruvate Kinase Deficiency
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1548
Presenting Author: Wilma Barcellini, M.D., Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Learn More >
Title: Characterizing Iron Overload by Age in Patients Diagnosed with Pyruvate Kinase Deficiency – a Descriptive Analysis from the Peak Registry
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1562
Presenting Author: Paola Bianchi, BSc, Ph.D., Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
Learn More >
Title: Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients With Pyruvate Kinase Deficiency
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1565
Presenting Author: Eduard J. van Beers, M.D., Van Creveldkliniek, Department of Internal Medicine, University Medical Center Utrecht, Utrecht, Netherlands
Learn More >
Title: Improvements in Patient-Reported Outcomes in Mitapivat-treated Patients With Pyruvate Kinase Deficiency: A Descriptive Analysis From the Phase 3 ACTIVATE Trial
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1735
Presenting Author: Kevin H. M. Kuo, M.D., Division of Hematology, University of Toronto, Toronto, Canada
Learn More >
Publication Only:
Title: Systematic Literature Review of Health-related Quality of Life Burden in Patients Across the Spectrum of Thalassemia
Abstract: PB2233
Lead Author: Khaled M. Musallam, M.D., Ph.D., Thalassemia Center, Burjeel Medical City, Abu Dhabi, United Arab Emirates
Learn More >
Title: Pharmacokinetic Modeling and Simulation to Support Mitapivat Dose Selection Used in Pediatric Phase III Studies
Abstract: PB2247
Lead Author: Ophelia Yin, Ph.D., Agios Pharmaceuticals, Cambridge, MA, United States
Learn More >
Title: Healthcare Resource Utilization of Adult Patients With Pyruvate Kinase Deficiency: A Real World Study Using US Veterans Health Administration Data
Abstract: PB2359
Lead Author: Erin Zagadailov, Pharm.D., Agios Pharmaceuticals, Cambridge, MA, United States
Learn More >
Collaborator-led Presentations
Oral Presentations:
Title: Evidence of Noninferiority of Mitapivat Versus Splenectomy in Murine Hereditary Spherocytosis
Session Date and Time: Saturday, June 11 at 16:30 – 17:45 CEST (Hall A2-A3)
Abstract: S273
Presenting Author: Alessandro Mattè, Ph.D., University of Verona and AOUI Verona, Verona, Italy
Learn More >
Poster Presentations:
Title: Pharmacodynamic Effects of AG-946, a Highly Potent Novel Activator of Pyruvate Kinase, In Ex Vivo Treatment of Red Blood Cells From Sickle Cell Disease Patients
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1492
Presenting Author: Minke A.E. Rab, M.D., Ph.D., Central Diagnostic Laboratory – Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
Learn More >
Title: Follow-up Results of a Phase 2 Study Assessing the Safety and Efficacy of Mitapivat Treatment, an Oral Pyruvate Kinase Activator, for up to 60 Weeks in Subjects With Sickle Cell Disease
Session Date and Time: Friday, June 10 at 16:30 – 17:45 CEST
Abstract: P1501
Presenting Author: Myrthe J. van Dijk, Ph.D., Department of Central Diagnostic Laboratory – Research, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
Learn More >
Publication Only:
Title: Adapting Patient Educational Approaches in Pyruvate Kinase Deficiency: Europe and North America Findings From the AAC Patient and Caregiver Survey
Abstract: PB2345
Presenting Author: Wilma Barcellini, M.D., Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Learn More >
Follow along with Agios at #EHA2022
;
For Jill and Tamara, living with #PKDeficiency isn’t just about managing a disease – it’s about the connections they’ve built with others on the same journey. These relationships provide vital support and strength. On #InternationalPKDeficiencyDay, we proudly partner with…
Our team came together for our annual #Thanksgiving potluck to celebrate a year filled with growth, collaboration, and gratitude. With delicious food, laughter, and heartfelt reflections, it was a perfect time to appreciate all that we've accomplished together. We are incredibly…
New Thal Pals Alert! Dive into Part 1 of our special two-part series on #nutrition with #thalassemia! We chat with Tamara Schryver, the president of @TwPKDnonprofit. Discover practical tips on nutrition, advice on supplements, and much more. Whether you're a patient, caregiver,…
